Carol Gemayel Barra, MD
Cardiovascular Disease · Wethersfield, CTNPI 1861591885
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Boehringer Ingelheim at 32.2% of the total.
Across 97 payments — averaging $51.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- E.r. Squibb & Sons, L.L.C.$661
- Novartis$645
- Pfizer$342
- Esperion Therapeutics, Inc.$250
- AstraZeneca$246
- plus $1K from 11 others
Across 55 payments — averaging $5092.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$128K
- Novartis$58K
- Boehringer Ingelheim$50K
- American Regent$26K
- Astrazeneca UK Limited$14K
- Boehringer Ingelheim Pharma GmbH & Co.kg$3K
- plus $394 from 2 others
What the payments were for
- Food & beverage$5,018100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 23 | $1,623 |
| E.r. Squibb & Sons, L.L.C. | 6 | $661 |
| Novartis | 14 | $645 |
| Pfizer | 13 | $342 |
| Esperion Therapeutics, Inc. | 2 | $250 |
| AstraZeneca | 3 | $246 |
| Lantheus Medical Imaging, Inc. | 13 | $198 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $189 |
| Abbott | 2 | $185 |
| Astellas Pharma US Inc | 10 | $177 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Scpharmaceuticals Inc. | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 1 | $108 |
| Actelion Pharmaceuticals US, Inc. | 1 | $82 |
| Johnson & Johnson | 3 | $43 |
| Merck | 1 | $22 |
| Boston Scientific | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,040 in reported general payments places this provider in the 75th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 549 | $545,300 |
| XareltoRivaroxaban | 269 | $268,029 |
| EntrestoSacubitril/Valsartan | 209 | $254,329 |
| Repatha SureclickEvolocumab | 52 | $63,351 |
| FarxigaDapagliflozin Propanediol | 66 | $50,555 |
| JardianceEmpagliflozin | 42 | $39,005 |
| BrilintaTicagrelor | 41 | $38,168 |
| NexletolBempedoic Acid | 21 | $11,601 |
| Metoprolol Succinate | 808 | $10,410 |
| Rosuvastatin Calcium | 612 | $7,306 |
| Atorvastatin Calcium | 636 | $6,577 |
| VascepaIcosapent Ethyl | 12 | $5,807 |
| Ezetimibe | 176 | $3,634 |
| LivaloPitavastatin Calcium | 11 | $3,611 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 99 | $2,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $342 | $545,300549 claims |
| Johnson & JohnsonXarelto | $43 | $268,029269 claims |
| NovartisEntresto | $645 | $254,329209 claims |
| AstraZenecaFarxiga, Brilinta | $246 | $88,723107 claims |
| Boehringer IngelheimJardiance | $1,623 | $39,00542 claims |
| Esperion Therapeutics, Inc.Nexletol | $250 | $11,60121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Wethersfield
- Komsu MamuyaWethersfield$25K
- Ahmed ElwanWethersfield$13K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.